# Newlimit

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/newlimit

- Industry: Biotechnology
- Headquarters: South San Francisco, US
- Website: www.newlimit.com
- Total disclosed funding: $670M
- Latest round: Series C (Jun 2, 2026)
- Investors on record: 16

## About

Based in the US, Newlimit, Inc. operates as a longevity pharma company that focuses on providing epigenetics programming and gene editing services. Based in California, US, and founded in 2021 by co-founders Brian Armstrong, Greg Johnson, and Jacob Kimmel, NewLimit, Inc., a.k.a. NewLimit operates as a biotechnology company that is working towards the radical extension of human health span using epigenetic reprogramming. In June 2026, Newlimit, Inc. raised USD 435 million in series C funding led by Founders Fund, with participation from other investors Lilly Ventures, Abstract, Valor Equity Partners, Human Capital and Kleiner Perkins. Thrive Capital, Greenoaks Capital, Quiet Capital, also participated in the round. The series C funding values Newlimit, Inc. at USD 3.1 billion post-money.

The company is developing medicines to treat age-related diseases by reprogramming the epigenome, which is a new therapeutic mechanism for restoring regenerative potential in aged and diseased cells. The company utilizes machine learning models, pooled perturbation screening, and functional genomics to solve epigenetic aging biology and disease by going through experiments.

## Funding rounds

- Series C, Jun 2, 2026, $435M — Kleiner Perkins, Lilly Ventures, Valor Equity Partners, Founders Fund, Greenoaks Capital, Thrive Capital, Quiet Capital, Human Capital, Abstract
- Series B, Oct 20, 2025, $45M — Kleiner Perkins, Eli Lilly and Company Limited, Boost VC, DUMAC, Abstract Ventures, Section 32, Human Capital, Dimension
- Series B, May 2, 2025, $130M — Kleiner Perkins, Valor Equity Partners, Founders Fund, Khosla Ventures, Human Capital, Dimension
- Series A, May 8, 2023, $60M — Kleiner Perkins, Founders Fund, Dimension

## Investors

- Kleiner Perkins (https://capitalatlas.ai/funds/kleiner-perkins) — Series A, Series B, Series C
- Founders Fund (https://capitalatlas.ai/funds/founders-fund) — Series A, Series B, Series C
- Dimension — Series A, Series B
- Valor Equity Partners (https://capitalatlas.ai/funds/valor-equity-partners) — Series B, Series C
- Khosla Ventures (https://capitalatlas.ai/funds/khosla-ventures) — Series B
- Human Capital (https://capitalatlas.ai/funds/human-capital) — Series B, Series C
- Eli Lilly and Company Limited — Series B
- Boost VC (https://capitalatlas.ai/funds/boost-vc) — Series B
- DUMAC — Series B
- Abstract Ventures (https://capitalatlas.ai/funds/abstract-ventures) — Series B
- Section 32 (https://capitalatlas.ai/funds/section-32) — Series B
- Lilly Ventures (https://capitalatlas.ai/funds/lilly-ventures) — Series C
- Greenoaks Capital (https://capitalatlas.ai/funds/greenoaks-capital) — Series C
- Thrive Capital (https://capitalatlas.ai/funds/thrive-capital) — Series C
- Quiet Capital (https://capitalatlas.ai/funds/quiet-capital) — Series C
- Abstract (https://capitalatlas.ai/funds/abstract) — Series C